Survival differences between HER2-0 and HER2-low-expressing breast cancer − A meta-analysis of early breast cancer patients
HER2-low (human epidermal growth factor receptor 2) breast cancer takes up 40–50% in all breast cancer subtypes. The survival difference between HER2-low and HER2-zero breast cancers remain uncertain. Therefore, the aim of this study was to compare survival outcome of the two subtypes and to explore...
Gespeichert in:
| Veröffentlicht in: | Critical reviews in oncology/hematology 2023-05, Vol.185, p.103962-103962, Article 103962 |
|---|---|
| Hauptverfasser: | , , , , , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 103962 |
|---|---|
| container_issue | |
| container_start_page | 103962 |
| container_title | Critical reviews in oncology/hematology |
| container_volume | 185 |
| creator | Yang, Ciqiu Zhang, Xiaoqi Chen, Yitian Li, Peiyong Zhang, Junsheng Xu, Aiqi Huang, Na Liang, Minting Chen, Yilin Wang, Kun |
| description | HER2-low (human epidermal growth factor receptor 2) breast cancer takes up 40–50% in all breast cancer subtypes. The survival difference between HER2-low and HER2-zero breast cancers remain uncertain. Therefore, the aim of this study was to compare survival outcome of the two subtypes and to explore the impact of hormone receptor status.
A comprehensive medical literature search was performed by searching PubMed, EMBASE, and the Cochrane Libraries up to August 2022. We included observational studies reporting hazard ratios (HRs) with corresponding 95% confidence intervals (CIs). The results of individual studies were pooled by random-effects models using Stata 16.0. Seventeen articles with a total of 78984 breast cancer patients were included in the meta-analysis.
We observed a statistically significant association between low HER2 expression and better breast cancer survival outcomes (OS: HR: 0.83; 95% confidence interval: 0.75, 0.90; DFS/RFS: HR: 0.83; 95% confidence interval: 0.75, 0.91). In a subgroup analysis, we found that HER2-low patients had better survival outcomes relative to hormone receptor-positive breast cancer patients (OS: HR: 0.87; 95% confidence interval: 0.81, 0.93; DFS/RFS: HR: 0.91; 95% confidence interval: 0.85, 0.96). Similarly, in triple-negative breast cancer patients, we also observed a positive association between HER2 low expression and better survival (OS: HR: 0.85; 95% confidence interval: 0.71, 0.98; DFS/RFS: HR: 0.85; 95% confidence interval: 0.74, 0.95).
Our study showed that HER2-low breast cancer had better survival outcomes compared to HER2 negative breast cancer in patients with early stage breast cancer, regardless of hormone receptor status.
This meta-analysis was registered with PROSPERO (CRD42022335704) on June 10, 2022.
All data generated or analysed during this study are included in this published article [and its supplementary information files].
•In the overall population, we found that patients with low HER2 expression breast cancer had better overall survival than patients with HER2 zero breast cancer.•Similarly, the survival advantage of disease-free survival or recurrence free survival can be demonstrated in hormone receptor positive and negative population cohorts. |
| doi_str_mv | 10.1016/j.critrevonc.2023.103962 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest_cross</sourceid><recordid>TN_cdi_proquest_miscellaneous_2793990958</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><els_id>S1040842823000501</els_id><sourcerecordid>2793990958</sourcerecordid><originalsourceid>FETCH-LOGICAL-c374t-c102013cb7a4ac5411848a50efcd25d1e306decd7c5641d358ef58c7658448703</originalsourceid><addsrcrecordid>eNqFkE1PGzEQhi3UiqTAX0A-9rLp-GPX3iNEFCohIfXjbDn2LHK02Q22E5oDd878xP6SbrQBpF56mtHoeWc0DyGUwYwBq74sZy6GHHHbd27GgYthLOqKH5Ep06ouQFbsw9CDhEJLrifkU0pLAJCyUsdkIqqaM6VhSp5-bOI2bG1LfWgajNg5THSB-RGxozdX33kB1HZ-bNv-scDf64gphe6eLiLalKmzQyjSP88v9IKuMNvCdrbdpZBo31C0sd39g65tDtjldEo-NrZNeHaoJ-TX16uf85vi9u762_zitnBCyVw4BhyYcAtlpXWlZExLbUvAxnleeoYCKo_OK1dWknlRamxK7VRVaim1AnFCPo9717F_2GDKZhWSw7a1HfabZLiqRV1DXeoB1SPqYp9SxMasY1jZuDMMzF6-WZp3-WYv34zyh-j54cpmsUL_Fny1PQCXI4DDr9uA0SQX9sZ9iOiy8X34_5W_uKicEg</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2793990958</pqid></control><display><type>article</type><title>Survival differences between HER2-0 and HER2-low-expressing breast cancer − A meta-analysis of early breast cancer patients</title><source>MEDLINE</source><source>Elsevier ScienceDirect Journals</source><creator>Yang, Ciqiu ; Zhang, Xiaoqi ; Chen, Yitian ; Li, Peiyong ; Zhang, Junsheng ; Xu, Aiqi ; Huang, Na ; Liang, Minting ; Chen, Yilin ; Wang, Kun</creator><creatorcontrib>Yang, Ciqiu ; Zhang, Xiaoqi ; Chen, Yitian ; Li, Peiyong ; Zhang, Junsheng ; Xu, Aiqi ; Huang, Na ; Liang, Minting ; Chen, Yilin ; Wang, Kun</creatorcontrib><description>HER2-low (human epidermal growth factor receptor 2) breast cancer takes up 40–50% in all breast cancer subtypes. The survival difference between HER2-low and HER2-zero breast cancers remain uncertain. Therefore, the aim of this study was to compare survival outcome of the two subtypes and to explore the impact of hormone receptor status.
A comprehensive medical literature search was performed by searching PubMed, EMBASE, and the Cochrane Libraries up to August 2022. We included observational studies reporting hazard ratios (HRs) with corresponding 95% confidence intervals (CIs). The results of individual studies were pooled by random-effects models using Stata 16.0. Seventeen articles with a total of 78984 breast cancer patients were included in the meta-analysis.
We observed a statistically significant association between low HER2 expression and better breast cancer survival outcomes (OS: HR: 0.83; 95% confidence interval: 0.75, 0.90; DFS/RFS: HR: 0.83; 95% confidence interval: 0.75, 0.91). In a subgroup analysis, we found that HER2-low patients had better survival outcomes relative to hormone receptor-positive breast cancer patients (OS: HR: 0.87; 95% confidence interval: 0.81, 0.93; DFS/RFS: HR: 0.91; 95% confidence interval: 0.85, 0.96). Similarly, in triple-negative breast cancer patients, we also observed a positive association between HER2 low expression and better survival (OS: HR: 0.85; 95% confidence interval: 0.71, 0.98; DFS/RFS: HR: 0.85; 95% confidence interval: 0.74, 0.95).
Our study showed that HER2-low breast cancer had better survival outcomes compared to HER2 negative breast cancer in patients with early stage breast cancer, regardless of hormone receptor status.
This meta-analysis was registered with PROSPERO (CRD42022335704) on June 10, 2022.
All data generated or analysed during this study are included in this published article [and its supplementary information files].
•In the overall population, we found that patients with low HER2 expression breast cancer had better overall survival than patients with HER2 zero breast cancer.•Similarly, the survival advantage of disease-free survival or recurrence free survival can be demonstrated in hormone receptor positive and negative population cohorts.</description><identifier>ISSN: 1040-8428</identifier><identifier>EISSN: 1879-0461</identifier><identifier>DOI: 10.1016/j.critrevonc.2023.103962</identifier><identifier>PMID: 36921780</identifier><language>eng</language><publisher>Netherlands: Elsevier B.V</publisher><subject>Breast Neoplasms - metabolism ; Breast Neoplasms - mortality ; Female ; HER2-low-expressing breast cancer ; HER2-zero breast cancer ; Humans ; Prognosis ; Proportional Hazards Models ; Receptor, ErbB-2 - genetics ; Receptor, ErbB-2 - metabolism ; Survival ; Triple Negative Breast Neoplasms - metabolism ; Triple Negative Breast Neoplasms - mortality</subject><ispartof>Critical reviews in oncology/hematology, 2023-05, Vol.185, p.103962-103962, Article 103962</ispartof><rights>2023 Elsevier B.V.</rights><rights>Copyright © 2023 Elsevier B.V. All rights reserved.</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed><citedby>FETCH-LOGICAL-c374t-c102013cb7a4ac5411848a50efcd25d1e306decd7c5641d358ef58c7658448703</citedby><cites>FETCH-LOGICAL-c374t-c102013cb7a4ac5411848a50efcd25d1e306decd7c5641d358ef58c7658448703</cites><orcidid>0000-0001-9851-7080</orcidid></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><linktohtml>$$Uhttps://www.sciencedirect.com/science/article/pii/S1040842823000501$$EHTML$$P50$$Gelsevier$$H</linktohtml><link.rule.ids>314,776,780,3536,27903,27904,65309</link.rule.ids><backlink>$$Uhttps://www.ncbi.nlm.nih.gov/pubmed/36921780$$D View this record in MEDLINE/PubMed$$Hfree_for_read</backlink></links><search><creatorcontrib>Yang, Ciqiu</creatorcontrib><creatorcontrib>Zhang, Xiaoqi</creatorcontrib><creatorcontrib>Chen, Yitian</creatorcontrib><creatorcontrib>Li, Peiyong</creatorcontrib><creatorcontrib>Zhang, Junsheng</creatorcontrib><creatorcontrib>Xu, Aiqi</creatorcontrib><creatorcontrib>Huang, Na</creatorcontrib><creatorcontrib>Liang, Minting</creatorcontrib><creatorcontrib>Chen, Yilin</creatorcontrib><creatorcontrib>Wang, Kun</creatorcontrib><title>Survival differences between HER2-0 and HER2-low-expressing breast cancer − A meta-analysis of early breast cancer patients</title><title>Critical reviews in oncology/hematology</title><addtitle>Crit Rev Oncol Hematol</addtitle><description>HER2-low (human epidermal growth factor receptor 2) breast cancer takes up 40–50% in all breast cancer subtypes. The survival difference between HER2-low and HER2-zero breast cancers remain uncertain. Therefore, the aim of this study was to compare survival outcome of the two subtypes and to explore the impact of hormone receptor status.
A comprehensive medical literature search was performed by searching PubMed, EMBASE, and the Cochrane Libraries up to August 2022. We included observational studies reporting hazard ratios (HRs) with corresponding 95% confidence intervals (CIs). The results of individual studies were pooled by random-effects models using Stata 16.0. Seventeen articles with a total of 78984 breast cancer patients were included in the meta-analysis.
We observed a statistically significant association between low HER2 expression and better breast cancer survival outcomes (OS: HR: 0.83; 95% confidence interval: 0.75, 0.90; DFS/RFS: HR: 0.83; 95% confidence interval: 0.75, 0.91). In a subgroup analysis, we found that HER2-low patients had better survival outcomes relative to hormone receptor-positive breast cancer patients (OS: HR: 0.87; 95% confidence interval: 0.81, 0.93; DFS/RFS: HR: 0.91; 95% confidence interval: 0.85, 0.96). Similarly, in triple-negative breast cancer patients, we also observed a positive association between HER2 low expression and better survival (OS: HR: 0.85; 95% confidence interval: 0.71, 0.98; DFS/RFS: HR: 0.85; 95% confidence interval: 0.74, 0.95).
Our study showed that HER2-low breast cancer had better survival outcomes compared to HER2 negative breast cancer in patients with early stage breast cancer, regardless of hormone receptor status.
This meta-analysis was registered with PROSPERO (CRD42022335704) on June 10, 2022.
All data generated or analysed during this study are included in this published article [and its supplementary information files].
•In the overall population, we found that patients with low HER2 expression breast cancer had better overall survival than patients with HER2 zero breast cancer.•Similarly, the survival advantage of disease-free survival or recurrence free survival can be demonstrated in hormone receptor positive and negative population cohorts.</description><subject>Breast Neoplasms - metabolism</subject><subject>Breast Neoplasms - mortality</subject><subject>Female</subject><subject>HER2-low-expressing breast cancer</subject><subject>HER2-zero breast cancer</subject><subject>Humans</subject><subject>Prognosis</subject><subject>Proportional Hazards Models</subject><subject>Receptor, ErbB-2 - genetics</subject><subject>Receptor, ErbB-2 - metabolism</subject><subject>Survival</subject><subject>Triple Negative Breast Neoplasms - metabolism</subject><subject>Triple Negative Breast Neoplasms - mortality</subject><issn>1040-8428</issn><issn>1879-0461</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2023</creationdate><recordtype>article</recordtype><sourceid>EIF</sourceid><recordid>eNqFkE1PGzEQhi3UiqTAX0A-9rLp-GPX3iNEFCohIfXjbDn2LHK02Q22E5oDd878xP6SbrQBpF56mtHoeWc0DyGUwYwBq74sZy6GHHHbd27GgYthLOqKH5Ep06ouQFbsw9CDhEJLrifkU0pLAJCyUsdkIqqaM6VhSp5-bOI2bG1LfWgajNg5THSB-RGxozdX33kB1HZ-bNv-scDf64gphe6eLiLalKmzQyjSP88v9IKuMNvCdrbdpZBo31C0sd39g65tDtjldEo-NrZNeHaoJ-TX16uf85vi9u762_zitnBCyVw4BhyYcAtlpXWlZExLbUvAxnleeoYCKo_OK1dWknlRamxK7VRVaim1AnFCPo9717F_2GDKZhWSw7a1HfabZLiqRV1DXeoB1SPqYp9SxMasY1jZuDMMzF6-WZp3-WYv34zyh-j54cpmsUL_Fny1PQCXI4DDr9uA0SQX9sZ9iOiy8X34_5W_uKicEg</recordid><startdate>202305</startdate><enddate>202305</enddate><creator>Yang, Ciqiu</creator><creator>Zhang, Xiaoqi</creator><creator>Chen, Yitian</creator><creator>Li, Peiyong</creator><creator>Zhang, Junsheng</creator><creator>Xu, Aiqi</creator><creator>Huang, Na</creator><creator>Liang, Minting</creator><creator>Chen, Yilin</creator><creator>Wang, Kun</creator><general>Elsevier B.V</general><scope>CGR</scope><scope>CUY</scope><scope>CVF</scope><scope>ECM</scope><scope>EIF</scope><scope>NPM</scope><scope>AAYXX</scope><scope>CITATION</scope><scope>7X8</scope><orcidid>https://orcid.org/0000-0001-9851-7080</orcidid></search><sort><creationdate>202305</creationdate><title>Survival differences between HER2-0 and HER2-low-expressing breast cancer − A meta-analysis of early breast cancer patients</title><author>Yang, Ciqiu ; Zhang, Xiaoqi ; Chen, Yitian ; Li, Peiyong ; Zhang, Junsheng ; Xu, Aiqi ; Huang, Na ; Liang, Minting ; Chen, Yilin ; Wang, Kun</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-LOGICAL-c374t-c102013cb7a4ac5411848a50efcd25d1e306decd7c5641d358ef58c7658448703</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2023</creationdate><topic>Breast Neoplasms - metabolism</topic><topic>Breast Neoplasms - mortality</topic><topic>Female</topic><topic>HER2-low-expressing breast cancer</topic><topic>HER2-zero breast cancer</topic><topic>Humans</topic><topic>Prognosis</topic><topic>Proportional Hazards Models</topic><topic>Receptor, ErbB-2 - genetics</topic><topic>Receptor, ErbB-2 - metabolism</topic><topic>Survival</topic><topic>Triple Negative Breast Neoplasms - metabolism</topic><topic>Triple Negative Breast Neoplasms - mortality</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Yang, Ciqiu</creatorcontrib><creatorcontrib>Zhang, Xiaoqi</creatorcontrib><creatorcontrib>Chen, Yitian</creatorcontrib><creatorcontrib>Li, Peiyong</creatorcontrib><creatorcontrib>Zhang, Junsheng</creatorcontrib><creatorcontrib>Xu, Aiqi</creatorcontrib><creatorcontrib>Huang, Na</creatorcontrib><creatorcontrib>Liang, Minting</creatorcontrib><creatorcontrib>Chen, Yilin</creatorcontrib><creatorcontrib>Wang, Kun</creatorcontrib><collection>Medline</collection><collection>MEDLINE</collection><collection>MEDLINE (Ovid)</collection><collection>MEDLINE</collection><collection>MEDLINE</collection><collection>PubMed</collection><collection>CrossRef</collection><collection>MEDLINE - Academic</collection><jtitle>Critical reviews in oncology/hematology</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Yang, Ciqiu</au><au>Zhang, Xiaoqi</au><au>Chen, Yitian</au><au>Li, Peiyong</au><au>Zhang, Junsheng</au><au>Xu, Aiqi</au><au>Huang, Na</au><au>Liang, Minting</au><au>Chen, Yilin</au><au>Wang, Kun</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Survival differences between HER2-0 and HER2-low-expressing breast cancer − A meta-analysis of early breast cancer patients</atitle><jtitle>Critical reviews in oncology/hematology</jtitle><addtitle>Crit Rev Oncol Hematol</addtitle><date>2023-05</date><risdate>2023</risdate><volume>185</volume><spage>103962</spage><epage>103962</epage><pages>103962-103962</pages><artnum>103962</artnum><issn>1040-8428</issn><eissn>1879-0461</eissn><abstract>HER2-low (human epidermal growth factor receptor 2) breast cancer takes up 40–50% in all breast cancer subtypes. The survival difference between HER2-low and HER2-zero breast cancers remain uncertain. Therefore, the aim of this study was to compare survival outcome of the two subtypes and to explore the impact of hormone receptor status.
A comprehensive medical literature search was performed by searching PubMed, EMBASE, and the Cochrane Libraries up to August 2022. We included observational studies reporting hazard ratios (HRs) with corresponding 95% confidence intervals (CIs). The results of individual studies were pooled by random-effects models using Stata 16.0. Seventeen articles with a total of 78984 breast cancer patients were included in the meta-analysis.
We observed a statistically significant association between low HER2 expression and better breast cancer survival outcomes (OS: HR: 0.83; 95% confidence interval: 0.75, 0.90; DFS/RFS: HR: 0.83; 95% confidence interval: 0.75, 0.91). In a subgroup analysis, we found that HER2-low patients had better survival outcomes relative to hormone receptor-positive breast cancer patients (OS: HR: 0.87; 95% confidence interval: 0.81, 0.93; DFS/RFS: HR: 0.91; 95% confidence interval: 0.85, 0.96). Similarly, in triple-negative breast cancer patients, we also observed a positive association between HER2 low expression and better survival (OS: HR: 0.85; 95% confidence interval: 0.71, 0.98; DFS/RFS: HR: 0.85; 95% confidence interval: 0.74, 0.95).
Our study showed that HER2-low breast cancer had better survival outcomes compared to HER2 negative breast cancer in patients with early stage breast cancer, regardless of hormone receptor status.
This meta-analysis was registered with PROSPERO (CRD42022335704) on June 10, 2022.
All data generated or analysed during this study are included in this published article [and its supplementary information files].
•In the overall population, we found that patients with low HER2 expression breast cancer had better overall survival than patients with HER2 zero breast cancer.•Similarly, the survival advantage of disease-free survival or recurrence free survival can be demonstrated in hormone receptor positive and negative population cohorts.</abstract><cop>Netherlands</cop><pub>Elsevier B.V</pub><pmid>36921780</pmid><doi>10.1016/j.critrevonc.2023.103962</doi><tpages>1</tpages><orcidid>https://orcid.org/0000-0001-9851-7080</orcidid></addata></record> |
| fulltext | fulltext |
| identifier | ISSN: 1040-8428 |
| ispartof | Critical reviews in oncology/hematology, 2023-05, Vol.185, p.103962-103962, Article 103962 |
| issn | 1040-8428 1879-0461 |
| language | eng |
| recordid | cdi_proquest_miscellaneous_2793990958 |
| source | MEDLINE; Elsevier ScienceDirect Journals |
| subjects | Breast Neoplasms - metabolism Breast Neoplasms - mortality Female HER2-low-expressing breast cancer HER2-zero breast cancer Humans Prognosis Proportional Hazards Models Receptor, ErbB-2 - genetics Receptor, ErbB-2 - metabolism Survival Triple Negative Breast Neoplasms - metabolism Triple Negative Breast Neoplasms - mortality |
| title | Survival differences between HER2-0 and HER2-low-expressing breast cancer − A meta-analysis of early breast cancer patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2025-01-24T17%3A44%3A44IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest_cross&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Survival%20differences%20between%20HER2-0%20and%20HER2-low-expressing%20breast%20cancer%20%E2%88%92%20A%20meta-analysis%20of%20early%20breast%20cancer%20patients&rft.jtitle=Critical%20reviews%20in%20oncology/hematology&rft.au=Yang,%20Ciqiu&rft.date=2023-05&rft.volume=185&rft.spage=103962&rft.epage=103962&rft.pages=103962-103962&rft.artnum=103962&rft.issn=1040-8428&rft.eissn=1879-0461&rft_id=info:doi/10.1016/j.critrevonc.2023.103962&rft_dat=%3Cproquest_cross%3E2793990958%3C/proquest_cross%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2793990958&rft_id=info:pmid/36921780&rft_els_id=S1040842823000501&rfr_iscdi=true |